In this insightful episode, host Lucy Chard is joined by Aurelio Arias from IQVIA to explore the transformative role of GLP-1 therapies in clinical obesity treatment and the technological advancements driving their success. Aurelio delves into how these medications are revolutionising care, offering hope to millions worldwide. A key focus is the upcoming patent expiry of semaglutide in 2026, which could significantly impact affordability and global access, sparking discussions on equitable distribution.